Concentrate for solution for infusion
- Antineoplastic agents. Monoclonal antibodies.
- Chimeric human-murine monoclonal antibody to the lymphocyte’s transmembrane antigen CD20, located on pre-B and mature B lymphocytes.
- R-MAB is approved to first-line treatment of B-cell non-Hodgkin’s lymphomas and chronic lymphocytic leukemia, rheumatoid arthritis and granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis.
- R-МAB is the first biosimilar of Mabtera®/Rituxan® in Belarus with the identity of the molecular structure and mechanisms of action, efficacy and safety profile proven in comparative clinical studies.